RenovaCare, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- RenovaCare, Inc. is a biotechnology and medical device firm engaged in the investigation, advancement, and commercialization of autologous cellular therapies for diverse medical and aesthetic uses. The company primarily focuses on the regeneration of human skin, the body's largest organ, and is developing its patented CellMist System and SkinGun technology. The CellMist System is designed to isolate stem cells from a patient's own skin, which are then gently applied to affected areas using the SkinGun, a specialized spray device, to promote natural wound healing. This innovative approach targets patients with burns, chronic and acute wounds, and scars, aiming to offer a swift and less invasive alternative to conventional skin grafting methods. In recent developments, RenovaCare received full Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration in May 2021 to conduct a clinical trial, designated CELLMIST 1, assessing the safety and feasibility of its SkinGun and CellMist System for treating burn wounds. However, patient enrollment for this trial was later paused in March 2022, influenced by lower-than-anticipated participation rates and ongoing legal challenges. The company also terminated its strategic research and development agreement with StemCell Systems GmbH in May 2022, which led to the closure of its R&D center in Berlin, Germany. The company, headquartered in Scottsdale, Arizona, continues to maintain its patent portfolio and intends to resume clinical development when additional funding becomes available. RenovaCare, Inc. was initially known as Janus Resources, Inc. before adopting its current name in January 2014.
Contrasting Biofrontera (NASDAQ:BFRI) & RenovaCare (OTCMKTS:RCAR)
RenovaCare (OTCMKTS:RCAR) Stock Crosses Above 50 Day Moving Average – Time to Sell?
RenovaCare Inc. Provides Notice of Proposed Derivative Settlement to All Record Holders and Beneficial Owners of RenovaCare, Inc.
Hagens Berman Sobol Shapiro LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of RenovaCare Securities - RCAR
RenovaCare Announces Termination of StemCell Systems R&D Agreement
SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating RenovaCare, Inc.
RenovaCare Announces Management Changes
RenovaCare Provides Clinical and Corporate Update
RM LAW Announces Investigation of RenovaCare, Inc.
SHAREHOLDER ALERT: Robbins LLP Investigates RenovaCare, Inc. (RCAR) on Behalf of Investors
RENOVACARE ALERT: Bragar Eagel & Squire, P.C. is Investigating RenovaCare, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
RCAR Long-Term Investor Alert: Did You Acquire RenovaCare, Inc. Before August 14, 2017? Should Management be Held Accountable for Investors Losses?
Last Few Hours to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of RenovaCare, Inc. (RCAR) Class Action and Lead Plaintiff Deadline: September 14, 2021
Last Few Hours to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of RenovaCare, Inc. (RCAR) Class Action and Lead Plaintiff Deadline: September 14, 2021
RCAR Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages RenovaCare, Inc. Investors with Losses to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
RCAR Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages RenovaCare, Inc. Investors with Losses to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm